CLRB
What one share of Cellectar Biosciences holds
Pharmaceutical Preparations
We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid ether drug conjugate ™ (PDC™) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects.
Cellectar Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.75 |
|---|---|
| Cash and investments | $4.12 |
| Book value | $3.62 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$550.86 | $0.96 | −$458.04 | — | $289.54 |
| 2021 | — | −$130.35 | $0.76 | −$122.72 | — | $142.70 |
| 2022 | — | −$135.18 | $0.96 | −$108.20 | — | $26.06 |
| 2023 | — | −$104.99 | $2.12 | −$81.60 | — | −$21.92 |
| 2024 | — | −$41.89 | $0.08 | −$38.52 | — | $9.31 |
| 2025 | — | −$8.35 | $0.00 | −$8.87 | — | $2.01 |